Mogamulizumab, a defucosylated anti-CCR4 antibody, can eliminate CCR4+ malignant T cells by antibody-dependent cellular cytotoxicity and has been approved by the FDA for patients with MF/SS (1–3). The gene discussed is CCR4; the disease is synovial sarcoma.